Chimerix (CMRX) Tops Q2 EPS by 12c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Chimerix (CMRX) Tops Q2 EPS by 12c

Chimerix Announces Second Quarter 2016 Financial Results

August 8, 2016 7:30 AM EDT

- European Commission Granted Orphan Drug Designation for Brincidofovir for the Treatment of Adenovirus -

- Conference Call at 8:30 a.m. ET Today -

DURHAM, N.C., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today reported financial results and provided a corporate update for the second quarter ended June 30, 2016.

We believe that the results of our ongoing development program for brincidofovir have demonstrated clear clinical evidence of its potent antiviral activity against three important DNA viruses:... More